AMPH
AmphastarCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bullish read is that the quarter showed commercial support from newer products and the Ipratropium Bromide HFA launch, while the stock's sharp post-earnings decline leaves room for recovery if margin pressure proves transitory and newer products continue scaling.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.3.
What can break
Glucagon revenue fell 56% and BAQSIMI revenue fell 15%, showing ongoing competition and unfavorable gross-to-net dynamics in important products.
Momentum
14
Value
71
Sentiment
54
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $22.00 · Bull $27.00 · Bear $16.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $22.00
Why
Momentum14 · Δ7d +7.2
Value71 · Δ7d -0.3
Sentiment54 · Δ7d -9.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
14
26% active weight
Current posture
7d trendImproving
Δ7d
+7.2
Δ21d
-10.1
Value
71
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
+0.4
Sentiment
54
34% active weight
Current posture
7d trendSoftening
Δ7d
-9.3
Δ21d
+8.9
Why this grade
Composite grade C. Momentum 13.8 / Value 71.0 / Sentiment 54.5
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$870.62M
Beta
0.87
Shares Out
44.09M
P/E (TTM)
11.8
P/S (TTM)
1.70
P/FCF (TTM)
11.06
Rev YoY
+0.4%
EPS YoY
-72.7%
Gross Margin
+45.2%
Op Margin
+20.7%
Net Debt
$370.76M
Current Ratio
3.85
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology